Rates of and Reasons for Failure of Commercial Human Immunodeficiency Virus Type 1 Viral Load Assays in Brazil-Reference-Cited by-同舟云学术

Rates of and Reasons for Failure of Commercial Human Immunodeficiency Virus Type 1 Viral Load Assays in Brazil

Published:2007-06 Issue:6 Volume:45 Page:2061-2063
ISSN:0095-1137
Container-title:Journal of Clinical Microbiology
language:en
Short-container-title:J Clin Microbiol

Author:

Drexler Jan Felix¹²,de Souza Luna Luciano Kleber¹,Pedroso Celia²,Pedral-Sampaio Diana Brasil²,Queiroz Artur T. L.³,Brites Carlos²,Netto Eduardo M.²,Drosten Christian¹

Affiliation:

1. Bernhard Nocht Institute for Tropical Medicine, Hamburg, Germany

2. Laboratório de Pesquisa em Infectologia, Hospital Universitário Prof. Edgard Santos, Salvador, Brazil

3. Laboratório de Saúde Avançada, Fiocruz, Salvador, Brazil

Abstract

ABSTRACT We examined failures of commercial human immunodeficiency virus type 1 (HIV-1) viral load assays of 1,195 plasma samples from Brazilian patients. Assay failure was assumed for samples in which the virus was undetectable by commercial assay but which tested positive by real-time reverse transcription-PCR of the HIV-1 long terminal repeat (LTR) region or if the viral load differed by >2 log 10 from that determined by LTR assay. Failure rates for Bayer Versant bDNA 3.0, Roche Amplicor Monitor v1.5, and bioMerieux NucliSens QT were 0.68, 0.47, and 4.33%, respectively. NucliSens may be inadequate for use in Brazil.

Publisher

American Society for Microbiology

Subject

Microbiology (medical)

Link

https://journals.asm.org/doi/pdf/10.1128/JCM.00136-07

Reference18 articles.

1. Evaluation of the Clinical Sensitivities of Three Viral Load Assays with Plasma Samples from a Pediatric Population Predominantly Infected with Human Immunodeficiency Virus Type 1 Subtype G and BG Recombinant Forms

2. Bongertz, V., D. C. Bou-Habib, L. F. Brigido, M. Caseiro, P. J. Chequer, J. C. Couto-Fernandez, P. C. Ferreira, B. Galvao-Castro, D. Greco, M. L. Guimaraes, M. I. Linhares de Carvalho, M. G. Morgado, C. A. Oliveira, S. Osmanov, C. A. Ramos, M. Rossini, E. Sabino, A. Tanuri, and M. Ueda, et al. 2000. HIV-1 diversity in Brazil: genetic, biologic, and immunologic characterization of HIV-1 strains in three potential HIV vaccine evaluation sites. J. Acquir. Immune Defic. Syndr.23:184-193.

3. Brindeiro, R. M., R. S. Diaz, E. C. Sabino, M. G. Morgado, I. L. Pires, L. Brigido, M. C. Dantas, D. Barreira, P. R. Teixeira, and A. Tanuri. 2003. Brazilian Network for HIV Drug Resistance Surveillance (HIV-BResNet): a survey of chronically infected individuals. AIDS (London)17:1063-1069.

4. Burgisser, P., P. Vernazza, M. Flepp, J. Boni, Z. Tomasik, U. Hummel, G. Pantaleo, and J. Schupbach. 2000. Performance of five different assays for the quantification of viral load in persons infected with various subtypes of HIV-1. J. Acquir. Immune Defic. Syndr.23:138-144.

5. Christopherson, C., J. Sninsky, and S. Kwok. 1997. The effects of internal primer-template mismatches on RT-PCR: HIV-1 model studies. Nucleic Acids Res.25:654-658.

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Development and validation of a vero cell-based suspension method for the detection of Zika virus;Revista Peruana de Medicina Experimental y Salud Pública;2023-09-26

2. A new multiplex RT-qPCR method for the simultaneous detection and discrimination of Zika and chikungunya viruses;International Journal of Infectious Diseases;2020-03

3. Sloths host Anhanga virus‐related phleboviruses across large distances in time and space;Transboundary and Emerging Diseases;2019-09-05

4. What Does the Future Hold for Yellow Fever Virus? (II);Genes;2018-08-21

5. Nucleoside analogs to manage sequence divergence in nucleic acid amplification and SNP detection;Nucleic Acids Research;2018-05-24